Skip to Main Content
 

Global Search Box

 
 
 
 

Files

File List


Thesis_FINAL_2-22.pdf (2.16 MB)

ETD Abstract Container

Abstract Header

Pharmacodynamics and Pharmacokinetics of Insulin Detemir and Insulin Glargine 300 U/ml in Healthy Dogs

Fink, Heidi Kathyrn
http://rave.ohiolink.edu/etdc/view?acc_num=osu1519227095240909

Abstract Details

2018, Master of Science, Ohio State University, Comparative and Veterinary Medicine.
Insulin glargine 300U/mL and insulin detemir are synthetic long-acting insulin analogs associated with minimal day-to-day variability or episodes of hypoglycemia in people. Here, eight healthy purpose-bred dogs each received 2.4 nmol/kg SQ injections of insulin detemir (0.1U/kg) and insulin glargine 300U/mL (0.4U/kg) on two different days, >1 week apart, in random order. Blood glucose (BG) was measured every 5 minutes and glucose was administered intravenously at a variable rate with the goal of maintaining BG within 10% of baseline BG ("isoglycemic clamp"). Endogenous and exogenous insulin were measured for up to 24 h after insulin injection. The effect of exogenous insulin was defined by glucose infusion rate or a decline in endogenous insulin. Isoglycemic clamps were generated in all eight dogs after detemir but only in four dogs after glargine. Median time to onset of action was delayed with glargine compared to detemir (4.0 h [3.3-5.8 h] versus 0.6 h [0.6-1.2 h], P = 0.002). There was no difference in time to peak (median [range] = 6.3 h [5.0-21.3 h] versus 4.3 h [2.9-7.4h], P = 0.15) or duration of action (16.3 h [6.1-20.1 h] versus 10.8 h [8.8-14.8 h], P = 0.21) between glargine or detemir, respectively. Glargine demonstrated a peakless time-action profile in 4/8 dogs. The total metabolic effect and peak action of detemir was significantly greater than glargine. Significant concentrations of glargine were detected in all but one dog following administration. Glargine might be better suited than detemir as a once-daily insulin formulation in some dogs based on its long duration of action and peakless time-action profile. Day-to-day variability in insulin action should be further assessed for both formulations.
Langston Catherine, DVM, DACVIM (Advisor)
Gilor Chen, DVM, PhD, DACVIM (Committee Member)
Lakritz Jeffrey, DVM, PhD, DACVIM (Committee Member)
62 p.
Endocrinology; Pharmacology
Diabetes Mellitus, Isoglycemic Clamp, Insulin

Recommended Citations

Citations

  • Fink, H. K. (2018). Pharmacodynamics and Pharmacokinetics of Insulin Detemir and Insulin Glargine 300 U/ml in Healthy Dogs [Master's thesis, Ohio State University]. OhioLINK Electronic Theses and Dissertations Center. http://rave.ohiolink.edu/etdc/view?acc_num=osu1519227095240909

    APA Style (7th edition)

  • Fink, Heidi. Pharmacodynamics and Pharmacokinetics of Insulin Detemir and Insulin Glargine 300 U/ml in Healthy Dogs. 2018. Ohio State University, Master's thesis. OhioLINK Electronic Theses and Dissertations Center, http://rave.ohiolink.edu/etdc/view?acc_num=osu1519227095240909.

    MLA Style (8th edition)

  • Fink, Heidi. "Pharmacodynamics and Pharmacokinetics of Insulin Detemir and Insulin Glargine 300 U/ml in Healthy Dogs." Master's thesis, Ohio State University, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=osu1519227095240909

    Chicago Manual of Style (17th edition)

osu1519227095240909
1,817
© 2018, all rights reserved.
This open access ETD is published by The Ohio State University and OhioLINK.